81
Participants
Start Date
June 30, 2010
Primary Completion Date
March 31, 2013
Study Completion Date
March 31, 2013
Imatinib
Patients will be randomly assigned to receive imatinib at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression, unacceptable toxicity, or withdrawal of consent.
Placebo
Patients will be randomly assigned to receive placebo at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression or withdrawal of consent.
Asan Medical Center, Seoul
Lead Sponsor
Asan Medical Center
OTHER